Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer

Documenti analoghi

• The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
  di: Gil, Hyun-Il, et al.
  Pubblicazione: (2020)
• Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
  di: Ricciuti, Biagio
  Pubblicazione: (2019)
• The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
  di: Gao, Xin, et al.
  Pubblicazione: (2016)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  di: Mok, T.S., et al.
  Pubblicazione: (2016)
• Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
  di: Nanjo, Shigeki, et al.
  Pubblicazione: (2018)